Proactive Investors - Run By Investors For Investors

Redx Pharma gets near £870,000 boost to working capital after repayment of loan previously written-off

Following the sale of significant assets by Redag Crop Protection Ltd, the repayment criteria for a loan previously granted to Redag by Redx in October 2014 has been met
Loan repayment
Redx confirmed it received a full cash repayment of £869,126, representing the original capital amount of £713,948 plus outstanding interest

Redx Pharma PLC (LON:REDX) has received an unexpected cash injection following the repayment of a loan it made which had previously been written off in its accounts, giving it a near £870,000 boost to working capital.

The AIM-listed drug discovery and development company, focused on cancer and fibrosis, said that following the sale of significant assets by Redag Crop Protection Ltd (Redag), the repayment criteria for a loan previously granted to Redag by the company in October 2014 has been met.

READ: Redx Pharma exploring options with interested parties for its NBTI programme after Deinove declines to exercise option

As a result, the group confirmed, it has now received a full cash repayment of £869,126, representing the original capital amount of £713,948 plus outstanding interest to date.

The group said, as disclosed in its accounts for the year ended 30 September 2018, the loan was originally treated as a non-current receivable, subsequently impaired, and ultimately derecognised as an asset in the accounts for the year ended 30 September 2017, as a result of the conditionality attached to the repayment.

Notwithstanding this,  it added, the directors continued to seek repayment and are pleased that this has now been achieved.

The funds will be used to augment working capital and, accordingly, the cash receipt will be disclosed in the group’s statement of comprehensive income for the year ending 30 September 2019.

View full REDX profile View Profile

Redx Pharma Plc Timeline

Related Articles

word cancer under magnifying glass
May 01 2019
The oncology-focused biotech is a mid-clinical-stage therapeutics company.
1537236236_main-better-use.jpg
September 18 2018
The company is utilising technology and big data to tackle the growing healthcare crisis and personalise treatment options for preventative care.
test tubes
April 16 2019
Summit Therapeutics' potential breakthrough targets C.difficile

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use